Bristol-Myers Squibb

Yahoo Finance • yesterday

Johnson & Johnson Financial Chief Sees ‘Clear Line of Sight’ to Double-Digit Growth by 2030

Johnson & Johnson has reinvented itself several times in recent years. Its latest earnings report signals the company has reinvented itself again. J&J posted adjusted earnings of $2.70 a share for the first quarter, narrowly beating out th... Full story

Yahoo Finance • yesterday

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter.

Johnson & Johnson stock gained on Tuesday after the pharmaceutical giant and medical device maker posted better-than-expected earnings and flagged strong sales growth in its first quarter. J&J posted adjusted earnings of $2.70 a share for... Full story

Yahoo Finance • 2 days ago

Replimune shares extend losses, tumble 56% after FDA rejects melanoma drug RP1

[Chemist developing new medicine in laboratory] Luis Alvarez * Replimune shares tumbled 56% in premarket trading on Monday after the FDA on Friday declined [https://seekingalpha.com/news/4574207-replimune-sees-layoffs-fda-snubs-cancer-d... Full story

Yahoo Finance • 3 days ago

Which Dividend Pharma Stock Should a Value Investor Choose Today?

Key Points Values aren't always easy to find in the pharma sector. Bristol Myers Squibb has stable revenue, plus a strong dividend payout. Its pipeline of drugs needs to keep growing to offset concerns around its legacy portfolio. 10 st... Full story

Yahoo Finance • 5 days ago

2 Recession Resistant Dividend Stocks to Buy Now While They're Still Cheap

Key Points CVS Health and Bristol Myers Squibb are built to handle the toughest recessions. Both companies have maintained or increased their dividends through downturns over the past two decades. Their shares look attractive right now.10... Full story

Yahoo Finance • 6 days ago

Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says

Large-cap and small- to medium-cap biopharmaceutical companies in BofA Securities' coverage are not PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 7 days ago

Cantor Fitzgerald Lifts Bristol Myers (BMY) Price Target but Flags Weak Q1 Catalyst

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Blue Chip Stocks with Highest Dividends.Cantor Fitzgerald Lifts Bristol Myers (BMY) Price Target but Flags Weak Q1 Catalyst On April 8, Cantor Fitzgerald raised the firm’s p... Full story

Yahoo Finance • 9 days ago

Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster

Neurocrine Biosciences logo 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking Neurocrine Biosciences (NASDAQ:NBIX) detailed its planned acquisition of Soleno Therapeutics on a conference call Monday, outlining the deal terms, the s... Full story

Yahoo Finance • 12 days ago

Mental Health Market Set to Surpass USD 668.62 Billion by 2035, Owing to the Increased Adoption of Digital Care and AI-Driven Therapies – SNS Insider

Austin, United States, April 03, 2026 (GLOBE NEWSWIRE) -- As per SNS Insider, The global Mental Health Market was estimated at USD 449.96 billion in 2025 and is projected to hit USD 668.62 billion by 2035, recording a CAGR of 4.04% over... Full story

Yahoo Finance • 13 days ago

Lilly Pushes Back on Making Drug Price Deals Permanent

This article first appeared on GuruFocus. Eli Lilly (LLY, Financials) is drawing a clear line in the ongoing debate over drug pricing, warning that making current agreements permanent could create bigger problems down the road. Warning!... Full story

Yahoo Finance • 13 days ago

JNJ Stock’s 60% Breakout: Why Wall Street is Torn

Johnson & Johnson (JNJ) stock is up 62% over the last twelve months. For a healthcare giant typically filed under "boring and defensive," that's unusual. The move reflects a combination of a leaner post-spinoff business and fundamentals th... Full story

Yahoo Finance • 14 days ago

No deal yet? Trump readies new tariffs on select drugmakers - report

[Senior woman buying medicine at drugstore] Luis Alvarez The Trump administration plans to impose tariffs on pharmaceutical companies that haven't agreed to lower U.S. drug prices, with an announcement expected as soon as Thursday, _Bloom... Full story

Yahoo Finance • 14 days ago

Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment

SAN DIEGO, April 01, 2026--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development c... Full story

Yahoo Finance • 14 days ago

Advanced Renal Cell Carcinoma Treatment Market to Grow by $3.1 Billion During 2026-2030: Global Industry Assessment Featuring Pfizer, Merck & Co., Bristol-Myers Squibb, AstraZeneca, Novartis and More

Company Logo Advanced Renal Cell Carcinoma Treatment MarketAdvanced Renal Cell Carcinoma Treatment Market·GlobeNewswire Inc. Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Advanced Renal Cell Carcinoma Treatment Market Report 2026" has... Full story

Yahoo Finance • 14 days ago

Renal Cell Carcinoma Market Report 2026-2030 & 2035: Increasing Immunotherapy and Precision Oncology Programs Drives Market Expansion, Reaching USD 6.09 Billion by 2030

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Renal Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive analysis, depicting global market size, regional shares,... Full story

Yahoo Finance • 15 days ago

Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030: Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer Lead the Industry

Company Logo Kidney Cancer Drugs MarketKidney Cancer Drugs Market·GlobeNewswire Inc. Dublin, March 31, 2026 (GLOBE NEWSWIRE) -- The "Kidney Cancer Drugs Market Report 2026" has been added to ResearchAndMarkets.com's offering. The globa... Full story

Yahoo Finance • 15 days ago

Ariel Global Fund Re-Added Bristol-Myers Squibb Company (BMY) on Pipeline Strength and Attractive Valuation

Ariel Investments, an investment management company, released its "Ariel Global Fund" fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Ariel Global Fund delivered solid results in 2025, rising +23.30% for t... Full story

Yahoo Finance • 15 days ago

Ovarian Cancer Drugs Market Outlook Report 2026-2030 Featuring Strategic Analysis of AstraZeneca, Roche, Bristol-Myers Squibb Company, Clovis Oncology, Pfizer and Other Key Players

Company Logo Ovarian Cancer Drugs MarketOvarian Cancer Drugs Market·GlobeNewswire Inc. Dublin, March 31, 2026 (GLOBE NEWSWIRE) -- The "Ovarian Cancer Drugs Market Report 2026" has been added to ResearchAndMarkets.com's offering. The rep... Full story

Yahoo Finance • 15 days ago

Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years

New survey, guided by patient advocacy input, seeks to elevate lived experience and community voice to better understand challenges in multiple myeloma care PRINCETON, N.J., March 31, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY... Full story

Yahoo Finance • 16 days ago

Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says

Alumis' (ALMS) recent phase 3 results for its psoriasis treatment envudeucitinib is "very positive" PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story